228 related articles for article (PubMed ID: 16102307)
1. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use.
MacDougall C; Harpe SE; Powell JP; Johnson CK; Edmond MB; Polk RE
Emerg Infect Dis; 2005 Aug; 11(8):1197-204. PubMed ID: 16102307
[TBL] [Abstract][Full Text] [Related]
2. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals.
Rogues AM; Dumartin C; Amadéo B; Venier AG; Marty N; Parneix P; Gachie JP
Infect Control Hosp Epidemiol; 2007 Dec; 28(12):1389-95. PubMed ID: 17994520
[TBL] [Abstract][Full Text] [Related]
3. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals.
MacDougall C; Powell JP; Johnson CK; Edmond MB; Polk RE
Clin Infect Dis; 2005 Aug; 41(4):435-40. PubMed ID: 16028149
[TBL] [Abstract][Full Text] [Related]
4. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010.
Nordmann P; Naas T; Fortineau N; Poirel L
Curr Opin Microbiol; 2007 Oct; 10(5):436-40. PubMed ID: 17765004
[TBL] [Abstract][Full Text] [Related]
5. Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study.
Lafaurie M; Porcher R; Donay JL; Touratier S; Molina JM
J Antimicrob Chemother; 2012 Apr; 67(4):1010-5. PubMed ID: 22240401
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
7. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Bosso JA; Mauldin PD
Antimicrob Agents Chemother; 2006 Jun; 50(6):2106-12. PubMed ID: 16723572
[TBL] [Abstract][Full Text] [Related]
8. [Bacterial etiology of nosocomial pneumonia and antimicrobial resistance in patients with and without antimicrobial treatment].
Weyland B; Perazzi B; García S; Rodríguez C; Vay C; Famiglietti A
Rev Argent Microbiol; 2011; 43(1):18-23. PubMed ID: 21491061
[TBL] [Abstract][Full Text] [Related]
9. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
Drusano GL; Preston SL; Fowler C; Corrado M; Weisinger B; Kahn J
J Infect Dis; 2004 May; 189(9):1590-7. PubMed ID: 15116294
[TBL] [Abstract][Full Text] [Related]
10. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
Dalhoff A; Schubert S
Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
[TBL] [Abstract][Full Text] [Related]
11. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.
Polk RE; Johnson CK; McClish D; Wenzel RP; Edmond MB
Clin Infect Dis; 2004 Aug; 39(4):497-503. PubMed ID: 15356812
[TBL] [Abstract][Full Text] [Related]
12. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
Marangon FB; Miller D; Muallem MS; Romano AC; Alfonso EC
Am J Ophthalmol; 2004 Mar; 137(3):453-8. PubMed ID: 15013867
[TBL] [Abstract][Full Text] [Related]
13. [Urinary tract infections].
Arakawa S
Nihon Rinsho; 2002 Nov; 60(11):2200-3. PubMed ID: 12440130
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolone use is not associated with the change in imipenem susceptibility of Pseudomonas aeruginosa in 25 hospitals.
Eagye KJ; Nicolau DP
Adv Ther; 2011 Apr; 28(4):326-33. PubMed ID: 21445549
[TBL] [Abstract][Full Text] [Related]
15. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
Rutter WC; Burgess DR; Burgess DS
Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
[TBL] [Abstract][Full Text] [Related]
16. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
Sullivan E; Bensman J; Lou M; Agnello M; Shriner K; Wong-Beringer A
Crit Care Med; 2014 Jan; 42(1):48-56. PubMed ID: 23963124
[TBL] [Abstract][Full Text] [Related]
17. Therapies against virulence products of Staphylococcus aureus and Pseudomonas aeruginosa.
Wiener-Kronish JP; Pittet JF
Semin Respir Crit Care Med; 2011 Apr; 32(2):228-35. PubMed ID: 21506059
[TBL] [Abstract][Full Text] [Related]
18. [A study of nosocomial infections by the comparison of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa].
Takesue Y; Kodama T; Santo T; Murakami Y; Nakamitsu A; Matsuura Y; Yokoyama T
Nihon Geka Gakkai Zasshi; 1994 Mar; 95(3):141-8. PubMed ID: 8177195
[TBL] [Abstract][Full Text] [Related]
19. Significance of fluoroquinolone-resistant Escherichia coli in urinary tract infections.
Shigemura K; Arakawa S; Miura T; Nakano Y; Tanaka K; Fujisawa M
Jpn J Infect Dis; 2008 May; 61(3):226-8. PubMed ID: 18503177
[TBL] [Abstract][Full Text] [Related]
20. [Antibiotic susceptibility of Staphylococcus aureus strains isolated in two university hospitals in Rabat, Morocco].
Elhamzaoui S; Benouda A; Allali F; Abouqual R; Elouennass M
Med Mal Infect; 2009 Dec; 39(12):891-5. PubMed ID: 19269758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
